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Smad4 protein, whose gene is coded at chromosome 18q21.1, is an important tumour suppressor that mediates transforming growth
factor-beta. It has been reported that inactivation of the Smad4 gene and allelic loss of chromosome 18q correlate with liver
metastasis and poorer prognosis in colorectal cancers. Utilising a recently developed method of immunohistochemical staining for
Smad4 protein, we focused on the specific impact of Smad4 protein expression on liver metastasis in colorectal cancer. We also
evaluated the association between chromosome18q deletion and liver metastasis. We selected 20 colorectal cancers with liver
metastasis for the experimental group, and 20 cases without liver metastasis for the control. In order to exclude the influence of
lymph node metastasis, all cases were lymph node negative. In addition, the two groups were matched for tumour depth, tumour
differentiation and tumour location. We compared the expression level of Smad4 protein immunohistochemically in these 20
matched pairs. We also compared the loss of heterozygosity status at chromosome 18q in these 20 matched pairs.
Immunohistochemical staining revealed a significant difference (P¼0.024) in the level of Smad4 protein between the two groups.
We also observed a significantly different (P¼0.0054) ratio of allelic deletion at chromosome 18q21. Smad4 protein expression level
and allelic loss at 18q21 are associated with the process of liver metastasis in colorectal cancers evaluated when excluding clinical and
pathological features except for liver metastasis.
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Colorectal cancer develops through multistep genetic alterations,
involving several oncogene and tumour suppressor genes (Vogel-
stein et al, 1988, 1989; Benhattar et al, 1993; Kinzler and
Vogelstein, 1996; Span et al, 1996; Kambara et al, 2004; Nassif
et al, 2004). Loss of heterozygosity (LOH) is one of the major types
of genetic inactivation, and the long arm of chromosome 18 is the
most frequently deleted region in colorectal cancers. To date, many
reports suggest that this deletion is a molecular predictor that
affects survival (Fearon et al, 1990; Jen et al, 1994; Chung, 1998;
Lanza et al, 1998; Ogunbiyi et al, 1998; Jernvall et al, 1999; McLeod
and Murray, 1999; Sarli et al, 2004). We too reported that the allelic
deletion of chromosome 18q was associated with poorer prognosis
in stage III colon cancer after adjuvant chemotherapy (Watanabe
et al, 2001, 2006). These reports suggest that there might be
tumour suppressor genes located at chromosome 18q, which has a
strong influence on survival. Smad4 gene, which mediates the
intracellular signalling pathway of transforming growth factor
(TGF)-beta receptor, has been detected as one of the target genes at
18q21 (Wang et al, 1995; Eppert et al, 1996; Hahn et al, 1996;
Thiagalingam et al, 1996; Carethers et al, 1998; Markowitz, 2000;
Fink et al, 2003; Alazzouzi et al, 2005; Li et al, 2005). Recently, an
immunohistochemical method for evaluating Smad4 protein has
been developed and several studies found higher frequency of
Smad4 protein inactivation in the cases with liver metastasis and in
the cases presenting unfavourable survival (Maitra et al, 2000;
Alazzouzi et al, 2005).
Currently, recurrences of colorectal cancers appear mainly as
lymph node metastasis or liver metastasis. This means that both
lymph node metastasis and liver metastasis have an influence on
survival after surgery. Furthermore, tumour depth and tumour
differentiation cannot be ignored when thinking of the malignancy
potential of the tumour. However, in all the previous reports
discussing the correlation of Smad4 protein and 18q deletion with
survival, tumour depth, lymph node metastasis and tumour
differentiations were not matched. Under such conditions, it was
impossible to detect which of these clinical and pathological
features that determine survival were truly associated with Smad4
protein expression and 18q deletion.
In this report, we attempted to focus on the specific influence of
Smad4 protein expression and 18q deletion on the development of
liver metastasis. In order to achieve this aim, we selected only
lymph node negative cases so as to exclude the influence of lymph
node invasion. Furthermore, we match tumour depth, tumour
differentiation and tumour locations, which have been reported to
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sinfluence LOH status and microsatellite instability. To the best of
our knowledge, this is the first report to assess the specific impact
of Smad4 protein and 18q deletion on the development of liver
metastasis under these conditions, which enabled us to exclude the
influence of clinical and pathological features other than liver
metastasis.
MATERIALS AND METHODS
Patient samples
Specimens were obtained during routine operations at the
Department of Surgical Oncology, Tokyo University Hospital,
from January 1980 to July 2005. Cases of familial adenomatous
polyposis and hereditary nonpolyposis colorectal carcinoma were
excluded from this study. No patient received cytotoxic therapy
before surgery. The study was approved by the Ethics Committee
of Tokyo University Hospital and patients gave their written
informed consent for the use of the specimens in advance.
There were 2783 cases of colorectal cancers operated on in our
hospital during this period and 261 cases were positive for liver
metastasis at the time of surgery. We selected 20 cases out of them,
which are confirmed negative for lymph node metastasis.
First, these 20 cases were assigned to the liver-metastasis (þ)
group. Next, 20 cases negative for liver metastasis and negative for
lymph node metastasis were assigned to the liver-metastasis ( )
group. The pathological T-classification, tumour location and
tumour differentiation of both groups were matched.
The clinical and pathological features of both groups are shown
in Table 1. Of the 40 patients in the two groups, 29 were male and
11 were female. The age distribution was from 26 to 79 years. There
was no statistically significant difference in the distribution of sex
and age between the liver-metastasis (þ) and liver-metastasis ( )
groups. Pathological staging in each case was according to the
UICC/TNM classification. T-classification and tumour differentia-
tion in each group were the same, as follows: T1, one (5%); T2, one
(5%); T3, 17 (85%); T4, one (5%); well-differentiated adenocarci-
noma, 19 (95%); poorly differentiated adenocarcinoma, one (5%).
The distribution of tumour location was also matched in both
groups: right colon, two (10%); left colon, four (20%); rectum, 14
(70%). The mean and median follow-up period were 1438 days and
1014 days for liver-metastasis ( ), during which no case of liver-
metastasis ( ) has been confirmed not to experience recurrence.
Immunohistochemical staining
All the samples for immunohistochemical analysis were obtained
from paraffin-embedded specimens. Serial sections were cut at a
thickness of 3mm for both Smad4 immunostaining and haematox-
ylin–eosin (H&E) staining.
The sections were deparaffinized with xylene and dehydrated
with 98% ethanol, placed in 0.01 M sodium citrate buffer (pH 6.0),
and heated in a microwave oven for three 7-min cycles (500W).
After washing three times in PBS, endogeneous peroxidase activity
was inhibited by incubation with 0.3% hydrogen peroxide in
methanol for 20min. Biotinylated rabbit anti-mouse immuno-
globulin and SAB complex which were supplied commercially
(Histofine SAB-PO(M) kit, Nichirei, Tokyo, Japan) were used as
reagents for the next step. The sections were incubated overnight
at a temperature of  41C with anti-SMAD4 monoclonal antibody
(Smad4(B-8):sc-7966, Santa Cruz Biotechnology, Inc., CA, USA) at
a dilution of 1:1000. Colour was then developed with diamino-
benzidine solution. Sections were then lightly counterstained with
a cocktail of Mayer’s/Lillie-Mayer’s haematoxyline and mounted.
Evaluation of Smad4 immunostaining
All the specimen immunostained for Smad4 protein were evaluated
without knowing their clinicopathological features. Smad4 staining
was predominantly observed in cytoplasm.
All the normal mucosa showed immunohistochemical staining
against Smad4 protein. The samples were evaluated as reported
previously (Alazzouzi et al, 2005). To evaluate the intensity of
Smad4 immunohistochemical staining, we used a semiquantitative
scale, where 0¼no Smad4 staining and 4 was the highest staining.
The samples that stained as strong as normal mucosa were scored
as 4, whereas the samples with no detectable immunohisto-
chemical staining were scored as zero. The grades of the remaining
weakly and partially stained samples were classified as previously
reported (Iacobuzio-Donahue et al, 2000). The samples in which
all the tumour cells showed positive but weaker stain than the
normal mucosa were scored as 3. And the samples that showed
diffuse stain were scored as 2, whereas the samples that showed
focal stain were scored as 1.
For statistical analysis, we classified these scores into three
groups: (1) no Smad4 (scored 0), (2) low Smad4 (scored 1 to 3) and
(3) high Smad4 (scored 4). Representative samples of Smad4
staining are shown in Figure 1.
Analysing the status of LOH
From the liver-metastasis (þ) and liver-metastasis ( ) groups, 12
T-matched pairs of tumours were available from their primary
frozen specimens. These specimens were used for LOH analysis.
The samples were snap-frozen in liquid nitrogen immediately after
being resected during routine operations and stored at  801C until
the DNA was extracted from each specimen using DNAeasy kit
(Qiagen, Tokyo, Japan). From other eight T-matched pair of
samples whose frozen specimens were not stored, we also obtained
DNA from paraffine-embedded specimens by microdissection
techniques as we described in the previous report (Kazama et al,
2006), resulting in obtaining all the 20 T-matched pairs of samples
in this LOH analysis.
To detect allelic loss, we employed three polymorphic markers;
D18s363, D18s474 and D18s46, mapped closely to Smad4 locus.
The primer sequences were obtained at the Genome Database. The
locations of the primers are shown in Figure 2. The sequence of
each primer is as follow: D18s363: 50-TTGGGAACTGCTCTA
CATTC-30(sense), 50-GCTTCATTCTCTCACTGGAT-30(antisense);
Table 1 Clinicopathological features of colorectal carcinomas
Group Liver metastasis (+) Liver metastasis ( )
Age 61.273.8 57.175.2 NS
Gender
Male 15 14
Female 5 6 NS
T-classification
T1 1 1
T2 1 1
T3 17 17
T4 1 1
Location
Right colon 2 2
Left colon 4 4
Rectum 14 14
Differentiation
Well 19 19
Moderately 0 0
Poorly 1 1
Liver metastasis ( ): a group of tumours without liver metastasis. Liver metastasis (+):
a group of tumours with liver metastasis.
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CAATGTCAGAAGG-30(antisense); D18s46: 50-GAATAGCAGGACC
TATCAAAGAGC-30(sense), 50-CAGATTAAGTGAAAACAGCATAT
GTG-30(antisense). Each primer pair was end-labelled with
fluorochrome 6-caboxyl-fluorescein (FAM), 4,7,20,40,50,70-hexa-
chloro-6-carboxylfluorescein (HEX) or NED (Applied Biosystems,
Tokyo, Japan).
Polymerase chain reaction (PCR) was performed in 10ml
reaction volumes containing 10  PCR Gold Buffer (Applied
Biosystems, Tokyo, Japan), 2.5mM MgCl2, 200ml deoxynucleotide
triphosphates mixture, 0.5mM of each primer, 20–40ng of
extracted DNA and 0.4U of AmpliTaq Gold DNA polymerase
(Applied Biosystems, Foster City, CA, USA). The DNA was
amplified in a thermal cycler (Gene Amp PCR system 9700,
Applied Biosystems) and PCR was performed according to the
following protocol: 10min at 951C for polymerase activation; 40
cycles at 941C for 30s, 561C for 1min and 721C for 1min; then, an
additional 30min at 701C. After denaturization at 951C for 5min,
the PCR products were electrophoresed and analysed on an
automated sequencer (ABI PRISM 3100 genetic analyser (Applied
Biosystems)), and the fluorescent signals from alleles of different
size were recorded and analysed using GeneScan version 3.1 and
Genotyper version 2.1 software (both software packages, Applied
Biosystems).
Assessment of LOH
For each pair of the samples, the normal mucosal DNA was used to
determine the allele size for the corresponding subject. Samples
whose normal mucosa showed only a single peak were considered
not informative for LOH. Samples showing two distinct peaks were
considered informative and were assessed for LOH. Loss of
heterozygosity was defined as a loss of one of the two peak alleles.
A sample showing LOH is shown in Figure 3.
Statistical analysis
Fisher’s exact test was used to determine the significance of
observed difference between the groups. A value of Po0.05 was
considered statistically significant.
AB C
Smad4
H&E
Figure 1 SMAD4 immunohistochemical staining of colorectal samples. (A) high Smad4, (B) low Smad4, (C) no Smad4. Samd4: Smad4
immunohistochemical staining. HE: corresponding samples of H&E staining.
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47M 48M
cen
46M 45M
tel
D18s363 D18s474 Smad4 DCC
Figure 2 Schematic representation of the microsatellite markers
analysed at 18q21.
174.17 197.94 174.19 198.01
541 392 1703 139
Figure 3 A representative example showing allelic loss. A representative
example showing allelic loss: two peaks of the normal sample correspond
to two alleles, and the tumour sample loses one of the peaks.
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Immunochemical staining of Smad4 protein
The results of immunohistochemical staining of Smad4 protein are
shown in Figure 4.
In liver-metastasis ( ) group, nine cases (45%) were classified as
high Smad4, eight (40%) as low Smad4 and three (15%) as no
Smad4. In liver-metastasis (þ) group, only one case (5%) was
classified as high Smad4, while 17 cases (85%) were classified as
low Smad4 and two (10%) as no Smad4. In other words, more
cases showed decreased intensity for Smad4 immunohistochemical
staining in liver-metastasis (þ) group compared to liver-
metastasis ( ) group.
We statistically compared the liver-metastasis (þ) and liver-
metastasis ( ) groups from the standpoint of Smad4 protein
immunohistochemical staining and found that Fisher’s exact test
showed a significant difference between both the groups
(P¼0.024).
Analysis of LOH status of Smad4
The results for individual primers are shown in Figure 5. The LOH
ratio was defined as the number of LOH cases divided by all the
informative cases in each primer. No cases in this study showed
microsatellite instability.
For D18s474, 28 out of 40 cases were informative. The LOH
ratios were 13% (two out of 16) in the liver-metastasis ( ) group
and 67% (eight out of 12) in the liver-metastasis (þ) group.
Fisher’s exact test showed that the cases in liver-metastasis (þ)
group showed significantly higher ratio of allelic loss at D18s474
compared with those in liver-metastasis ( ) group (P¼0.0054).
For D18s46, 24 out of 40 cases were informative, and the LOH
ratios were 30% (three out of 10) in the liver-metastasis ( ) group
vs 71% (10 out of 15) in the liver-metastasis (þ) group, with no
significant difference (P¼0.095) found between the groups. For
the primer D18s363, 21 out of 40 cases were informative, and 18%
(two out of 11) of the cases demonstrated LOH in the liver-
metastasis ( ) group vs 70% (seven out of 10) in the liver-
metastasis (þ) group. This result showed a statistically significant
difference (P¼0.030).
Correlation between LOH at chromosome 18q21 and
Smad4 immunohistochemical staining
We then examined if LOH at chromosome 18q21 had a direct effect
on Smad4 protein level in 40 samples (Figure 6). Those samples
that showed allelic loss in any of these three primers were classified
positive for LOH. The samples in liver-metastasis (þ) group
showed more cases of low Smad4 compared to liver-metastasis ( )
group, although statistical analysis did not show a significant
difference (P¼0.59).
DISCUSSION
In the current study, we selected only lymph node negative cases and
matched for T-classification, tumour locations and tumour differ-
entiations between liver-metastasis (þ)/( ) groups, and demon-
strated significant statistical differences between these two groups in
Smad4 protein level and chromosome 18q deletion. This is the first
report to focus on the specific impact of liver metastasis on Smad4
protein expression and chromosome 18q deletion with clinical
features other than liver metastasis being matched. Decreases in
Smad4 protein expression and chromosome 18q deletion are known
to be characteristic risk factors of liver metastasis.
It has been proven that the loss of chromosome 18q, which is
present in about 70% of colorectal cancers, is related to tumour
progression, recurrence and poor prognosis. Jen et al (1994)
reported that patients with stage II colorectal cancer and
chromosome 18q allelic loss show worse prognosis than those
without 18q allelic loss. They pointed out that stage II colorectal
cancer patients with 18q allelic loss have a similar prognosis to
stage III patients. Moreover, they argued that stage II colorectal
cancer patients without 18q allelic loss show similar prognosis to
those with stage I patients. A study by Lanza et al (1998) also
showed similar results in that patients with stage II disease whose
tumour had no 18q allelic loss demonstrated a 5-year survival rate
of 96%, while those with stage II disease and 18q allelic loss
showed a 5-year survival rate of only 54%. Ogunbiyi et al (1998)
reported that Chromosome 18q allelic loss was significantly
associated with reduced disease-free and disease-specific survival
in patients with stage II (P¼0.05 and P¼0.0156) and III disease
(P¼0.038 and P¼0.032). We showed that microsatellite stable
(MSS) patients with stage III colorectal cancer showed poor
*P = 0.024
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Figure 4 SMAD4 immunohistochemical staining of colorectal tumours.
liver-metastasis ( ): a group of tumours without liver metastasis. liver-
metastasis (þ): a group of tumours with liver metastasis.
*P = 0.030 P = 0.095 *P = 0.0054
Liver 
metastasis ( +)
Liver 
metastasis ( −)
LOH analysis of each primer
L
O
H
 
r
a
t
i
o
Primers
D18s363 D18s46 D18s474
0
0.2
0.4
0.6
0.8
1
Figure 5 Loss of heterozygosity patterns of each primer. liver-metastasis
( ): a group of tumours without liver metastasis. liver-metastasis (þ):a
group of tumours accompanying liver metastasis.
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Figure 6 Correlation between LOH and Smad4 immunohistochemical
staining.
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(Watanabe et al, 2001). We also recently argued that 18q allelic loss
is a significant prognostic value in colorectal cancer (Watanabe
et al, 2006).
In the current study, we demonstrated that there was a
significant statistical association of chromosome 18q deletion with
liver metastasis, which has a strong impact on survival after
surgery. This study was the first to evaluate the influence on liver
metastasis of 18q deletion where tumour depth, lymph node
invasion, tumour differentiation and tumour location were
excluded, and confirmed that 18q allelic loss is a useful marker
of liver metastasis.
There have been numerous efforts to detect the target genes at
chromosome 18q in colorectal carcinogenesis and cancer progres-
sion, and two putative genes have been detected. The DCC gene
located at 18q21 was first considered to be an important target
gene and to play an important role in colorectal pathogenesis
(Fearon et al, 1990; Shibata et al, 1996). However, there have been
several cases with 18q deletion in which no inactivation of DCC
was observed, implying the existence of another target gene (Cho
et al, 1994). Subsequently, Smad4 gene was detected as another
target at 18q21.1, whose mutations were detected up to 35% of
colorectal cancers (Shibata et al, 1996).
In a previous study, the genomic inactivation of Smad4 was
reported to correlate with carcinogenesis, tumour progression and
poorer prognosis in colorectal caners. Miyaki et al (1999) reported
that they found no Smad4 mutation in adenomas and intramucosal
carcinomas, although the frequency of the mutation increased as
the invasiveness of the tumour grew. Furthermore, they found a
higher frequency of mutation in colorectal cancers with distant
metastasis compared to those without distant metastasis. Their
study strongly indicated that the Smad4 gene correlates with
malignancy in the advanced stage and is the target gene on
18q21.1, the locus indicative of tumour progression and poorer
prognosis when deleted.
Recently, an immunohistochemical assay of Smad4 protein has
been developed and several studies indicated that Smad4 protein
inactivation affected survival. Anirban Maitra et al classified
patients according to TNM stage and examined Smad4 protein
expression for the first time. In their study, they found no Smad4
protein inactivation in stage I patients, 8% in stage II, 6% in stage
III and 22% in stage IV patients, indicating that tumour
progression correlates with Smad4 protein inactivation. They also
classified patients into two groups according to the status of liver
metastasis, and indicated a borderline significant correlation
between Smad4 staining and liver metastasis (P¼0.05) (Maitra
et al, 2000). Alazzouzi et al (2005) studied 86 Dukes’ C colorectal
cancer patients and showed that patients with Dukes’ C tumours
expressing high Smad4 protein levels had significantly better
overall (Po0.025) and disease-free (Po0.013) survival than
patients with low levels by immunohistochemical staining. We,
too, recently discussed the association between Smad4 level and
prognosis in colorectal cancers. Previous reports suggested that
Smad4 protein inactivation correlates with liver metastasis;
however, the groups consisted of various T- and N-stage patients.
In this study, lymph node negative cases were matched for T-
classification, tumour depth and tumour location and demon-
strated a statistically significant difference (P¼0.024) in Smad4
protein expression level between liver-metastasis (þ)/( ) groups.
This result confirmed more accurately the previous report that
Smad4 protein inactivation is related to the process or the risk of
liver metastasis.
In conclusion, our results showed that both chromosome 18q
deletion and Smad4 protein expression are associated with liver
metastasis in colorectal cancers, and that they both play an
important role in the development of liver metastasis.
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